Neurology

Response to levodopa: long-term follow-up

 

REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 An Australian longitudinal study of patients with Parkinson’s disease has found that cognitive decline is associated with progressive deteriorations in motor function (Alty et al. AD/PD 2009; 1999).

Read More

TOPICS:

The effects of stress in Parkinson’’s disease

 

REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 The dopaminergic system is involved in mediating the effects of stress on motor function, which may explain the observation that stress can lead to the onset of parkinsonian symptoms or accelerate the progression of Parkinson’s disease.

Read More

TOPICS:

Comparing treatments for behavioural and psychological symptoms

 

REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009A single-centre open trial in Sweden has compared the use of galantamine and risperidone for the treatment of behavioural and psychological symptoms in dementia (BPSD) (Freund-Levi. AD/PD; 1290).

Read More

TOPICS:

Diabetes a risk factor for MCI, Alzheimer’s disease

 

REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 – German researchers have analysed data from the Longitudinal Study on Adult Development and Aging to assess the impact of type 2 diabetes on the development of mild cognitive impairment (MCI) and Alzheimer’s disease (Toro et al. AD/PD; 427; published as Toro et al. J Alzheimers Dis 2009;16: 687-691)). All subjects were born in the period 1930-1932.

Read More

TOPICS:

Alzheimer’’s disease and HMG CoA reductase variants

 

REPORT FROM THE 9th INTERNATIONAL CONFERENCE AD/PD, PRAGUE, CZECH REPUBLIC, MARCH 11-15, 2009 Genetic variants in HMG CoA reductase may influence the risk of Alzheimer’s disease, according to the results of a study of French Canadians from Eastern Canada (Legault et al. AD/PD; 1626).

Read More

TOPICS: